1,310
Views
2
CrossRef citations to date
0
Altmetric
Research Paper

Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study

, &
Pages 748-754 | Received 13 Jul 2018, Accepted 16 Oct 2018, Published online: 05 Dec 2018

References

  • Jeong SH, Lee HS, Hepatitis A. clinical manifestations and management. Intervirology. 2010;53(1):15–19. doi:10.1159/000252779.
  • WHO. Position paper on hepatitis A vaccines. Weekly Epidemiol Rec. 2012;87(28/29):261–276.
  • Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28(41):6653–6657. doi:10.1016/j.vaccine.2010.08.037.
  • Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. Int J Health Geogr. 2011;10:57. doi:10.1186/1476-072X-10-57.
  • WHO. Meeting of the strategic advisory group of experts on immunization, November 2011 - conclusions and recommendations. Weekly Epidemiol Rec. 2012;87(1):1–16.
  • Zhuang GH, Pan XJ, Wang XL. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. Vaccine. 2008;26(35):4608–4616. doi:10.1016/j.vaccine.2008.05.086.
  • Barzaga BN. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine. 2000;18(Suppl 1):S61–4.
  • Li RC, Li Y, Yi N, Huang L, Wan Z, Zhang Y, Rasuli A. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China. Pediatr Infect Dis J. 2013;32(2):e77–81. https://www.ncbi.nlm.nih.gov/pubmed/23334341.
  • Vidor E, Dumas R, Porteret V, Bailleux F, Veitch K. Aventis pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. European J Clin Microbiol & Infect Dis. 2004;23(4):300–309. doi:10.1007/s10096-003-1094-0.
  • Abarca K, Ibanez I, Perret C, Vial P, Zinsou JA. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Int J Infect Dis. 2008;12(3):270–277. doi:10.1016/j.ijid.2007.08.006.
  • Castillo de Febres O, Chacon de Petrola M, Casanova de Escalona L, Naveda O, Naveda M, Estopinan M, Bordones G, Zambrano B, Garcia A, Dumas R. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine. 1999;18(7–8):656–664.
  • Dagan R, Greenberg D, Goldenbertg-Gehtman P, Vidor E, Briantais P, Pinsk V, Athias O, Dumas R. Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine. 1999;17(15–16):1919–1925.
  • Lopez EL, Del Carmen Xifro M, Torrado LE, De Rosa MF, Gomez R, Dumas R, Wood SC, Contrini MM. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J. 2001;20(1):48–52.
  • EU Clinical Trials Register ECT. Safety of two doses of avaxim® 80U pediatric (inactivated hepatitis A vaccine) administered 6 months apart in healthy toddlers, children and adolescents aged 12 months to 15 years in China 2016. [ accessed 2018 Sept 24]. https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003190-14/results#trialInformationSection.
  • Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–872.